Enfortumab vedotin Not Yet Recruiting Phase 2 Trials for Transitional Cell Carcinoma of the Bladder / High Grade Urothelial Carcinoma / Bladder Cancer Treatment

Indications	Status	Purpose	Phase
DBCOND0028556 (Transitional Cell Carcinoma of the Bladder) DBCOND0153452 (High Grade Urothelial Carcinoma) DBCOND0028389 (Bladder Cancer)	Not Yet Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT05656235	Renal Retention in High Grade Upper Tract Urothelial Cancer	Enfortumab vedotin (DB13007) Pembrolizumab (DB09037)